Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Olema Pharmaceuticals, Inc.

Ticker
OLMA
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include executive appointments, analyst coverage initiations, notable stock price volatility, and inclusion in breast cancer stock discussions.

Recent developments:
  • Olema appointed Jason O'Byrne as CFO in August 2026 [N2].
  • Wolfe Research initiated coverage with a peer perform recommendation in March 2026 [N3].
  • Stifel and Piper Sandler initiated coverage with buy and overweight recommendations respectively in early 2026 [N7,N8].
  • The stock experienced a nearly 300% increase followed by a 33.4% decline over four weeks in early 2026, with notable option activity and insider selling reported [N4,N5,N6].
  • Olema was highlighted among breast cancer stocks during Breast Cancer Awareness Month in October 2026 [N1].
Overview

Olema Pharmaceuticals is focused on next-generation targeted therapies for breast cancer, leveraging deep expertise in endocrine-driven cancers and nuclear receptors. Its lead product candidate, palazestrant, is an oral small molecule with dual CERAN and SERD activity targeting ER+/HER2- breast cancer. Palazestrant is in late-stage clinical development with pivotal Phase 3 trials ongoing for monotherapy and combination with ribociclib. The company also develops OP-3136, a novel KAT6 inhibitor in early clinical trials. Olema has no approved products or revenue and relies on third parties for manufacturing. The company aims to establish palazestrant as the endocrine therapy of choice in metastatic breast cancer and expand its pipeline through internal research and collaborations.

Executive summary

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer, primarily ER+/HER2- metastatic breast cancer. Its lead candidate, palazestrant, is in pivotal Phase 3 trials as monotherapy and in combination with ribociclib. The company also develops OP-3136, a KAT6 inhibitor in early clinical stages. Olema has no approved products or revenue and has incurred significant net losses, with strong liquidity as of September 30, 2026. The company faces typical clinical-stage biotech risks including capital needs, regulatory approval, and competition. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for OLMA

Bull case model:

Olema's lead candidate palazestrant has demonstrated promising clinical activity and favorable pharmacokinetics, with ongoing pivotal Phase 3 trials in multiple metastatic breast cancer settings. Its oral dual CERAN/SERD mechanism may overcome limitations of current endocrine therapies, potentially positioning it as a preferred treatment. The collaboration with Novartis for ribociclib supply and combination trials enhances development capabilities. The early-stage KAT6 inhibitor OP-3136 adds pipeline diversification. Strong liquidity and recent analyst coverage support operational continuity and investor interest.

Bear case model:

Olema has no approved products and has incurred substantial net losses, with ongoing need for significant capital to fund clinical development and operations. Clinical trials carry inherent risks of failure or delays, and regulatory approval is uncertain. Competition from other endocrine therapies and targeted agents is intense. The company relies on third-party manufacturing and collaborations, which may pose operational risks. Market acceptance of any approved products is not guaranteed. Financial leverage and macroeconomic uncertainties may constrain flexibility and increase risks to business continuity.

Moat:

Olema's moat is based on its proprietary dual-mechanism oral therapy palazestrant, which combines complete estrogen receptor antagonism and selective degradation, addressing limitations of existing endocrine therapies. Its deep scientific understanding of ER biology and mechanisms of resistance, along with clinical collaborations with established pharma companies like Novartis, support its development efforts. The company's focus on unmet needs in ER+/HER2- metastatic breast cancer and potential CNS penetration for brain metastases further differentiate its pipeline. However, as a clinical-stage biotech, the moat depends on successful clinical and regulatory outcomes and competitive positioning.

Risks overview
Risks summary
The biggest risks for Olema Pharmaceuticals stem from its lack of approved products, substantial capital needs, clinical development uncertainties, and competitive and regulatory challenges.
Risks details:

• No Approved Products: Olema has no products approved for commercial sale, making it difficult to evaluate current business and future viability [S2].
• Capital Requirements: The company requires substantial additional capital to finance operations and clinical development. Failure to raise capital on acceptable terms may force delays or reductions in programs [S2].
• Clinical Development Risks: Clinical trials are lengthy, expensive, and uncertain. Failure at any stage could significantly harm business prospects [S2].
• Competition: Olema faces significant competition from other therapies that may be more effective, safer, or less expensive [S2].
• Regulatory Approval Uncertainty: Obtaining regulatory approvals is uncertain and critical for commercialization [S2].
• Operational Risks: Dependence on third parties for manufacturing and clinical trials, potential IT/data security issues, and organizational growth challenges pose risks [S2].

FINAL FORECAST FOR OLMA

Final take one line
Olema Pharmaceuticals is a clinical-stage biotech with high visibility into its breast cancer-focused pipeline, clinical programs, financials, and risks.
Final take 12 to 24 month view

Business trends: Advancement of palazestrant through pivotal Phase 3 trials as monotherapy and in combination, early clinical development of OP-3136, and strategic collaborations.
Execution milestones: Completion and reporting of Phase 3 trial results, regulatory submissions, and potential commercial launch preparations.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, capital requirements, competitive landscape, and operational dependencies.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovery, development, and commercialization of next-generation targeted therapies for breast cancer and other cancers [S1].
  • The lead product candidate is palazestrant (OP-1250), an oral small molecule acting as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), targeting ER+/HER2- breast cancer [S1].
  • Palazestrant is in late-stage clinical development, including a pivotal Phase 3 monotherapy trial (OPERA-01) initiated in November 2023 for second/third-line metastatic breast cancer, with top-line results anticipated in fall 2026 [S1].
  • A Phase 3 trial (OPERA-02) is ongoing for palazestrant in combination with ribociclib in frontline metastatic breast cancer, supported by a clinical collaboration and drug supply agreement with Novartis [S1].
  • The second product candidate, OP-3136, is a novel oral KAT6 inhibitor in early clinical development, with IND cleared in late 2024 and Phase 1 trial enrolling patients [S1].
  • Olema has no products approved for commercial sale and has not generated revenue from product sales [S1,S2].
  • The company relies on third parties for manufacturing and does not own manufacturing facilities [S1].
  • The global ER+/HER2- metastatic breast cancer market is estimated at approximately $20 billion, with potential market opportunities for palazestrant up to $5 billion in second/third-line and $10 billion in first-line settings in the US and EU [S1].
  • Olema's strategy includes advancing palazestrant through late-stage clinical development, establishing it as endocrine therapy of choice in metastatic ER+ breast cancer, exploring additional indications including brain metastases, expanding product portfolio, and collaborating with partners for development and commercialization [S1].
  • The company has incurred net losses since inception, including a net loss of $73.6 million for the three months ended September 30, 2026, and had an accumulated deficit of $787.4 million as of that date [S2].
  • Olema's cash and equivalents were $47.5 million and short-term investments $366.2 million as of September 30, 2026, with a current ratio of 6.12 and cash ratio of 5.98, indicating strong liquidity [S2].
  • Olema has a loan agreement with a credit facility up to $100 million, with $3 million drawn as of September 30, 2026, and amendments extending maturity and draw periods [S2].
  • The company faces risks including no approved products, need for substantial additional capital, clinical development uncertainties, competition, regulatory approval challenges, and operational risks [S2].
  • Recent news includes appointment of Jason O'Byrne as CFO, initiation of coverage by Wolfe Research with peer perform recommendation, and multiple analyst coverage initiations and recommendations [N2,N3,N7,N8].
  • Olema's stock experienced significant price volatility with a nearly 300% increase followed by a 33.4% decline over four weeks in early 2026, with notable option activity and insider selling reported [N4,N5,N6].
  • Olema is highlighted among breast cancer stocks during Breast Cancer Awareness Month in October 2026 [N1].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-16 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-10-16 | www.nasdaq.com | 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month | https://www.nasdaq.com/articles/4-breast-cancer-stocks-watch-during-breast-cancer-awareness-month
  • N2 | 2026-08-13 | www.nasdaq.com | Olema Appoints Jason O'Byrne As CFO | https://www.nasdaq.com/articles/olema-appoints-jason-obyrne-cfo
  • N3 | 2026-03-27 | www.nasdaq.com | Wolfe Research Initiates Coverage of Olema Pharmaceuticals (OLMA) with Peer Perform Recommendation | https://www.nasdaq.com/articles/wolfe-research-initiates-coverage-olema-pharmaceuticals-olma-peer-perform-recommendation
  • N4 | 2026-03-18 | www.nasdaq.com | Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner | https://www.nasdaq.com/articles/olema-pharmaceuticals-olma-loses-334-4-weeks-heres-why-trend-reversal-may-be-around-corner
  • N5 | 2026-03-16 | www.nasdaq.com | Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch | https://www.nasdaq.com/articles/biotech-stock-nearly-300-draws-687-million-bet-breast-cancer-drug-targets-2027-launch
  • N6 | 2026-03-09 | www.nasdaq.com | Olema Pharmaceuticals Becomes Oversold (OLMA) | https://www.nasdaq.com/articles/olema-pharmaceuticals-becomes-oversold-olma
  • N7 | 2026-02-11 | www.nasdaq.com | Stifel Initiates Coverage of Olema Pharmaceuticals (OLMA) with Buy Recommendation | https://www.nasdaq.com/articles/stifel-initiates-coverage-olema-pharmaceuticals-olma-buy-recommendation
  • N8 | 2026-01-08 | www.nasdaq.com | Piper Sandler Initiates Coverage of Olema Pharmaceuticals (OLMA) with Overweight Recommendation | https://www.nasdaq.com/articles/piper-sandler-initiates-coverage-olema-pharmaceuticals-olma-overweight-recommendation
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine